title: Anti-arrhythmic and hemodynamic effects of oxy nifedipine, oxy nimodipine, oxy nitrendipine and oxy nisoldipine.
abstract: Our previous studies have established cardio-protective effects of furnidipine and its active metabolites. We therefore decided to compare the influence of oral and intravenous administration of furnidipine, nifedipine, nitrendipine and nimodipine to examine their effects on hemodynamics and arrhythmias. Since dihydropyridines are oxidatively metabolized in the body and the oxidized metabolites are among the final products, we studied the influence of four oxidized dihydropyridines (oxy nifedipine, oxy nimodipine, oxy nitrendipine and oxy nisoldipine) on the same parameters. In vivo model of ischemia- and reperfusion-induced arrhythmias of rats was used. Dihydropyridines were administered 5 mg/kg orally (24 and 1 h before ischemia) or 5 μg/kg intravenously (10 min before ischemia). 20 mg/kg of the oxidized dihydropyridines was given orally (24 and 1 h before ischemia). The dihydropyridines exhibited significant anti-arrhythmic actions after both forms of administration but their influence on blood pressure was differential and contrasting and depended on route of administration. The oxidized dihydropyridines imparted strong protection against lethal arrhythmias while exerting differential influences on blood pressure with oxy nifedipine and oxy nisoldipine being hypertensive and oxy nitrendipine being most normotensive. The differential effects observed with the dihydropyridines after the two routes of administration lend strength to the hypothesis that their metabolites may have a significant role in mediating the actions of the parent drug. The strong anti-arrhythmic action of the oxidized dihydropyridines along with their differential effect on blood pressure could indicate their potential use as cardio-protective drugs in certain groups of patients.
authors: Chair and Department of Pharmacology, Medical University of Silesia, Poland. kas-k2@o2.pl
authors: Katarzyna A
authors: KA
authors: Mitręga
authors: Benoy
authors: B
authors: Varghese
authors: Maurycy
authors: M
authors: Porc
authors: Tadeusz F
authors: TF
authors: Krzemiński
mesh_terms: D061605:Administration, Intravenous; D000284:Administration, Oral; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000737:chemistry* / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000503:physiopathology / Q000517:prevention & control*; D001794:Blood Pressure / Q000187:drug effects; D004095:Dihydropyridines / Q000008:administration & dosage / Q000737:chemistry* / Q000627:therapeutic use*; D006321:Heart / Q000187:drug effects / Q000503:physiopathology; D006439:Hemodynamics / Q000187:drug effects*; D008297:Male; D009543:Nifedipine / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use; D009553:Nimodipine / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use; D015737:Nisoldipine / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use; D009568:Nitrendipine / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use; D010084:Oxidation-Reduction; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D000889:Anti-Arrhythmia Agents; D004095:Dihydropyridines; D015737:Nisoldipine; D009553:Nimodipine; D009568:Nitrendipine; D009543:Nifedipine